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Melanoma is unusual among tumours of adults in that it is
generally defined by its morphology, not its anatomic location.
Melanoma arises from melanocytes that are found mostly in the
skin, but also in the bowel and the uveal and genital tracts. Only
melanoma of the skin is considered here, including the very rare
melanomas of the scrotal skin, defined both by anatomic location
(ICD-9 1877, ICD-10 C632) and morphology.
Melanoma of the skin has been increasing rapidly in the United
Kingdom since the 1960s, as in many other countries (Coleman
et al, 1993). Only prostate cancer rose more rapidly during the
1990s (Quinn et al, 2001). Almost 7000 cases are now diagnosed in
England and Wales each year, almost double again the figure for
1990 (3700), itself double the number of cases in 1970. Melanoma
now ranks as the sixth most frequent malignancy in women,
accounting for 3% of tumours. The annual incidence rate in
women (15 per 100 000) is higher than in men (12), and the risk is
2–3 times higher among the most affluent groups: both features
are unusual for a malignancy. The increase in risk in England and
Wales affects all ages, both sexes and all socioeconomic groups,
although the rise has been more marked in the elderly, in women
and in the most affluent (data not shown).
Increases in mortality during the 1970s and 1980s were less
marked than for incidence, and mortality trends slowed further
during the 1990s, with a rise of only 8% in men and an actual fall of
12% in women. Stable or falling mortality alongside rapidly
increasing incidence suggests substantial gains in survival.
We report here the survival patterns for over 55 000 adults who
were diagnosed with malignant melanoma of the skin in England
and Wales during 1986– 1999 and were followed up to 31
December 2001. They represent 92% of patients eligible for
inclusion in the analyses. Some 2% of patients were excluded
because their vital status was not known when the data were
extracted for analysis on 2 November 2002, a further 3% because
their duration of survival was zero or unknown, and another 3%
because the melanoma was not their first invasive primary
malignancy (data not shown).
The skin of the leg and hip is still the most common loca-
tion for a melanoma, but the distribution has shifted towards the
trunk over the last 30 years. The leg and hip accounted for 45% of all
melanomas in the early 1970s, but this figure has fallen steadily,
reaching 32% by the late 1990s. The proportion arising on the skin of
the trunk excluding the scrotum rose from 18 to 25% over the same
period. The skin of the face, head and neck has accounted for a
steady 15–16% throughout these three decades.
Virtually all the tumours were assigned to one of the morphology
codes for malignant melanoma, and only 2% had a nonspecific
morphology code. As melanomas of the skin are primarily identified
by an anatomic site code (ICD-9 172, ICD-10 C43), rather than their
morphology, this suggests a high standard of diagnostic accuracy.
The proportion of tumours coded as superficial spreading melanoma
rose from 18% to 33% during the period 1986–1999, although the
proportion classified simply as malignant melanoma fell from 70 to
56%. The annual number of melanomas has trebled since the early
1970s, so even this large proportional change does not adequately
reflect the increase in superficial spreading melanoma, for which the
number of cases in England and Wales almost doubled from 840 to
1500 cases a year between 1991 and 1999 alone (data not shown). This
increase may well be real, and although it could also reflect a change
in how pathologists describe and classify melanoma, a detailed review
of melanoma incidence trends suggests a remarkable constancy in the
pathological definition of melanoma over time and place, at least up
to the late 1980s (van der Esch et al, 1991).
SURVIVAL TRENDS
Survival from melanoma is high, and substantially higher in
women than in men. For men diagnosed during 1986–1990,
relative survival was 91% at 1 year and 71% at 5 years; the
corresponding figures for women were 96 and 85%. After
adjustment for deprivation, 1-year survival in men rose by
approximately 2% every 5 years, reaching 94% for men diagnosed
during 1996– 1999 (Table 1, Figure 1). Five-year survival rose
more rapidly (4% every 5 years), reaching 78% for men diagnosed
1996– 1999. For women, deprivation-adjusted increases in survival
were smaller, and not statistically significant.
Short-term predictions of survival, using hybrid analysis (Brenner
and Rachet, 2004) of the survival probabilities observed during
2000–2001, suggests the underlying increase in survival will continue
in the near future (Table 1).
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DEPRIVATION
Survival up to 5 years remains 4– 6% lower among men in the
more deprived groups than among the more affluent, but the
deprivation gap did not widen significantly during the 1990s.
The deprivation gap in survival for women fell during the 1990s,
and it is now only 1%. The fall in the deprivation gap in
5-year survival, 2.6% every 5 years, was statistically significant
(Table 2, Figure 2).
Hybrid analysis of patients’ survival experience during
2000– 2001 suggests that these patterns will persist for at least
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 90.9 (90.1, 91.7) 91.9 (91.2, 92.5) 93.8 (93.1, 94.4) 1.7** (0.5, 3.0) 93.8 (92.9, 94.6)
Women 95.8 (95.3, 96.2) 96.2 (95.8, 96.6) 96.9 (96.5, 97.3) 0.0 (0.7, 0.8) 96.9 (96.3, 97.4)
5 years Men 70.6 (69.3, 72.0) 74.4 (73.3, 75.5) 77.9 (76.5, 79.2) 4.0** (1.6, 6.3) 78.1 (76.5, 79.6)
Women 85.2 (84.3, 86.0) 87.3 (86.6, 88.0) 89.5 (88.6, 90.3) 0.3 (1.2, 1.8) 89.8 (88.7, 90.7)
10 years Men 64.6 (63.0, 66.1) 69.5 (68.1, 70.9) 3.9 (1.0, 8.9) 73.2 (71.3, 75.0)
Women 81.4 (80.4, 82.3) 84.2 (83.2, 85.1) 0.9 (2.3, 4.2) 86.7 (85.4, 87.9)
CI¼ confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival
estimated with cohort or complete approach (1986–1990, 1991–1995,
1996–1999) or hybrid approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative
survival (%) by sex and calendar period of diagnosis: England and Wales,
adults (15–99 years) diagnosed during 1986–1999 and followed up
to 2001.
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5 years, with a significant deprivation gap for men and a much
smaller socioeconomic difference in survival among women
(Table 2).
COMMENT
Survival from melanoma of the skin in England and Wales is high,
and the fact that 5-year survival is increasing so much more
rapidly than 1-year survival – more so for melanoma than for any
of the other malignancies examined here – suggests a real increase
in survival and cure, presumably attributable to earlier diagnosis
and/or improved treatment. The socioeconomic gradient in
survival also appears to be stable or declining.
These encouraging trends continue those seen since the
1970s and 1980s, with more rapid increases for men than women
in both short-term and long-term survival, and less marked
socioeconomic inequality in survival. Thus the difference in
5-year survival between women and men fell from 21%
for patients diagnosed in the early 1970s to 14% by the
late 1980s (Coleman et al, 1999), and now to 12% by the late 1990s
in these data. Similarly, the deprivation gap in survival between the
most affluent and most deprived patients diagnosed during 1981–
1985 was approximately 6% at 1 year and 12% at 5 years. This fell to
4 and 8%, respectively, for those diagnosed during 1986–1990, and
now to 6 and 1% for patients diagnosed during 1996–1999.
Survival is higher for melanomas less than 1.5 mm in thickness
at diagnosis, when radical surgery may still be curative; the
prognosis for thicker tumours or disseminated disease is poor. Earlier
diagnosis also contributes to socioeconomic differences in survival.
Survival patterns in Scotland suggest a possible explanation
for the overall trends and the change in socioeconomic
gradient in survival in England and Wales. Increasing
survival in Scotland, following a public education campaign
to encourage earlier diagnosis, has been ascribed to earlier
diagnosis and thinner lesions (MacKie et al, 1992). In a popu-
lation study of 3000 cases diagnosed in the west of
Scotland during 1979–1993, thin melanomas were more
common in the affluent, but the proportion of thin tumours
increased more in deprived groups during this period (MacKie and
Hole, 1996).
The fact that survival rates in Scotland for melanoma – but
not for any other tumour – are significantly higher in
Scotland than the European average for both men and women
(Berrino et al, 2003), tends to reinforce the conclusion that
the public awareness campaign in Scotland has been valuable
in fostering earlier diagnosis, higher survival and less inequality in
survival.
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men 3.1* (5.5, 0.7) 2.3* (4.3, 0.3) 3.5** (5.2, 1.7) 0.3 (1.9, 1.2) 4.2** (6.7, 1.7)
Women 2.8** (4.1, 1.4) 1.7** (2.9, 0.5) 1.3* (2.5, 0.1) 0.8 (0.2, 1.7) 1.4 (3.1, 0.2)
5 years Men 5.6** (9.5, 1.6) 5.8** (9.1, 2.5) 6.2** (10.2, 2.3) 0.4 (3.3, 2.6) 7.3** (11.8, 2.7)
Women 5.8** (8.3, 3.2) 3.6** (5.7, 1.4) 0.9 (3.4, 1.6) 2.6** (0.7, 4.4) 1.9 (5.0, 1.1)
10 years Men 6.0** (10.4, 1.6) 4.8* (8.9, 0.6) 1.2 (4.8, 7.3) 4.9 (10.3, 0.5)
Women 7.8** (10.7, 4.9) 5.2** (8.0, 2.3) 2.7 (1.4, 6.8) 3.2 (6.9, 0.6)
CI¼ confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
Survival from melanoma of the skin in England and Wales
B Rachet et al
S49
British Journal of Cancer (2008) 99(S1), S47 – S49& 2008 Cancer Research UK
